12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xalkori crizotinib: Additional Phase III data

Additional data from the open-label, international Phase III PROFILE 1007 trial in 347 patients with previously treated ALK-positive advanced NSCLC showed that twice-daily 250 mg oral Xalkori led to a median PFS of 7.7 months, the primary endpoint, vs. 3 months for investigator's choice of pemetrexed or docetaxel (p<0.001). Xalkori also met the secondary endpoint of improving ORR vs. investigator's choice of chemotherapy (65% vs. 20%, p<0.001). However, an interim analysis of the secondary OS endpoint showed no significant improvement with Xalkori compared to chemotherapy. Specifically, Xalkori led...

Read the full 419 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >